Awakn Announces The Findings From Phase II A/B Study Are To Be Published In American Journal Of Psychiatry
November 4, 2021
Ryan Allway November 4th, 2021 Worlds’s First Controlled Study To Investigate Ketamine-Assisted Psychotherapy TORONTO, CANADA, November 4, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that the ‘Ketamine in the Reduction of Alcoholic... Read more
